Pharmaceuticals, Biotechnology and Life Sciences
– EMA concludes that the primary endpoint and supportive secondary endpoints from prior successful Phase 3 studies conducted in the…
NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) — Lexeo Therapeutics, Inc. (Nasdaq: LXEO) (“Lexeo”), a clinical stage genetic medicine company…
— Poster to be presented at American College of Rheumatology Convergence 2025 – BRISBANE, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE)…
PISCATAWAY, N.J., Oct. 20, 2025 (GLOBE NEWSWIRE) — IMPALA, a global consortium dedicated to advancing digital and analytics-driven quality in…
One-time infusion of anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy in 16 patients with metastatic uveal melanoma in the ongoing…
OCALA, Fla., Oct. 20, 2025 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced it…
Activity Report for Quarter Ended September 30, 2025 (Appendix 4C)NEW YORK, Oct. 19, 2025 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO;…
Responses were rapid and durable, and tumour shrinkage was observed in 82 percent of patients1 New findings from this investigational…
PluvictoTM plus standard of care (ARPI + ADT) significantly reduced risk of progression or death by 28% (HR 0.72) versus…
Median progression free survival (PFS) has not been reached in the cohort of patients with salivary gland cancer with PFS…